3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Conditions
Carcinoma, Non-Small-Cell Lung
10
Uterine Cervical Neoplasms
8
Squamous Cell Carcinoma of Head and Neck
6
Stomach Neoplasms
5
Triple Negative Breast Neoplasms
4
Pancreatic Neoplasms
4
Carcinoma, Renal Cell
4
Advanced Solid Tumors
4
Urinary Bladder Neoplasms
3
Recurrence
3
Melanoma
3
Lung Neoplasms
3
Cholangiocarcinoma
3
Solid Tumor
2
Ovarian Neoplasms
2
Neoplasms
2
Neoplasm Metastasis
2
Kidney Neoplasms
2
Esophageal Neoplasms
2
Colorectal Neoplasms
2
Breast Neoplasms
2
Adenocarcinoma Of Esophagus
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Urothelial Bladder Carcinoma
1
Thyroid Carcinoma, Anaplastic
1
Thymoma
1
Solid Tumors
1
Solid Tumor, Unspecified, Adult
1
Sarcoma
1
Interventions
Cisplatin
56
Radiotherapy
34
Radiotherapy, Intensity-Modulated
28
Magnetic Resonance Spectroscopy
24
Radiation
20
Carboplatin
19
pembrolizumab
17
Specimen Handling
16
Platinum
14
1,2-diaminocyclohexaneplatinum II citrate
14
Paclitaxel
13
Cetuximab
13
Fluorouracil
10
Surgical Procedures, Operative
9
Docetaxel
9
Biopsy
9
Taxes
8
Chemoradiotherapy
8
Nivolumab
7
Fluorodeoxyglucose F18
7
Drug Therapy
7
durvalumab
6
Surveys and Questionnaires
6
fludarabine
5
X-Rays
5
Observation
5
Cyclophosphamide
5
aldesleukin
4
Standard of Care
4
Radiosurgery
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Oropharyngeal Neoplasms
×
zimberelimab
×
Clear all
NCT04892875
2023-11-30
PANTHEoN
Vanderbilt-Ingram Cancer Center
Phase 1
Withdrawn